2 170

Cited 0 times in

Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients

Authors
 Inho Kim  ;  Youngil Koh  ;  Sung-Soo Yoon  ;  Seonyang Park  ;  Byoung Kook Kim  ;  Dae-Young Kim  ;  Jung-Hee Lee  ;  Kyoo-Hyung Lee  ;  June-Won Cheong  ;  Hong-Kee Lee  ;  Sung-Hyun Kim  ;  Hyuk Kim  ;  Young Don Joo  ;  Sang-Min Lee  ;  Jong-Ho Won  ;  Sung-Kyu Park  ;  Dae-Sik Hong  ;  Se-Hyung Kim  ;  Sang Kyun Sohn  ;  Chul-Soo Kim  ;  Eunkyung Park  ;  Min Kyoung Kim  ;  Moo Rim Park  ;  Je-Hwan Lee  ;  Yoo Hong Min 
Citation
 American Journal of Hematology, Vol.88(1) : 10-15, 2013 
Journal Title
 American Journal of Hematology 
ISSN
 0361-8609 
Issue Date
2013
Abstract
We performed a phase II trial to evaluate the efficacy and safety of the modified fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) regimen in elderly acute myeloid leukemia (AML) patients. Elderly (≥60 years) AML patients who had not previously received chemotherapy were enrolled in the study. Patients received two consecutive cycles of m-FLAI chemotherapy as an induction. The m-FLAI regimen comprised fludarabine (25 mg/m(2) , days 1-4), cytarabine (1,000 mg/m(2) , days 1-4), and attenuated-dose idarubicin (5 mg/m(2) , days 1-3). The primary end point was complete remission (CR) rate. Secondary end points were overall survival (OS), event-free survival (EFS), and treatment-related mortality (TRM). There were 108 patients (median age 68.4 years, M:F = 64:44) enrolled in the study. CR was achieved in 56.5% of patients, and the TRM rate was 21.3%. Median OS and median EFS were 10.2 and 6.6 months, respectively. The mortality at 30 and 60 days was 15 and 21%, respectively. Performance status and comorbidity did not have prognostic value in this patient cohort. Bone marrow expression of CD117 was associated with increased EFS and OS. m-FLAI is an effective induction regimen for previously untreated AML in elderly patients. In addition, bone-marrow CD117 expression is an independent favorable prognostic factor in elderly AML patients. (ClinicalTrials.gov number, NCT01247493).
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/86689
DOI
10.1002/ajh.23337
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
Yonsei Authors
민유홍(Min, Yoo Hong) ; 정준원(Cheong, June-Won)
사서에게 알리기
  feedback
Full Text
http://onlinelibrary.wiley.com/doi/10.1002/ajh.23337/abstract;jsessionid=D00C7A38C0DAF6C87242A7BB4C5F513D.f04t03
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse